Catastrophic pharmacare is a catastrophe

 Why the provinces don’t need $3 billion in federal tax dollars for flawed prescription drug policies Last week, the CD Howe Institute called on Ottawa to give provinces nearly $3-billion to establish national standards for catastrophic drug coverage and to mandate a system of transparent price negotiations with pharmaceutical drug

Is Waiting Longer for New Prescription Drug Approvals Necessarily a Bad Thing?

 Why Canada’s ‘slow and low’ approach to new pharmaceuticals may be the prudent approach. The newest report from Canada’s brand name drug makers on access to new drugs has one key message: compared to other countries, Canada goes slow and low.  New drugs are slower to be covered by our